Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.66 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.60 |
| ▸ | FRK | P42685 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818740 | 0.86 | MAPK14 (0.74) | MAPK14HSPB1EPHA3FRK | |
| SCHEMBL5632508 | 0.86 | MAPK14 (1.00) | MAPK14MAPK11HSPB1CYP2C9 | |
| SCHEMBL3085538 | 0.84 | MAPK14 (0.65) | MAPK14MAPK11HSPB1CYP2C9 | |
| SCHEMBL4814686 | 0.82 | MAPK14 (0.69) | MAPK14HSPB1EPHA3FRK | |
| SCHEMBL5462512 | 0.81 | MAPK14 (0.90) | MAPK14MAPK11HSPB1CYP2C9 | |
| SCHEMBL4820912 | 0.81 | MAPK14 (0.66) | MAPK14HSPB1EPHA3FRK | |
| SCHEMBL5629868 | 0.80 | MAPK14 (0.88) | MAPK14MAPK11HSPB1CYP2C9 | |
| SCHEMBL6620463 | 0.79 | MAPK14 (1.00) | MAPK14MAPK11HSPB1CYP2C9 | |
| SCHEMBL6744546 | 0.79 | MAPK14 (1.00) | MAPK14MAPK11HSPB1CYP2C9 | |
| SCHEMBL5112623 | 0.78 | MAPK14 (0.72) | MAPK14MAPK11HSPB1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112046-A1 | 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-17 | — | — | US | disclosed |
| US-7166623-B2 | 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20050090491-A1 | 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112046-A1 | 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors | MAPK1, MAPK3, MAPKAPK2 | MAPK14 7/4885MAPK11 36/4885HSPB1 1187/4885 |
| US-20050090491-A1 | 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GRK4, MAPK4, MAPK1 | MAPK14 19/4885MAPK11 64/4885HSPB1 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.